NRD
DYN icon

Nebula Research & Development’s Dyne Therapeutics DYN Stock Holding History

Nebula Research & Development’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,834
Closed -$187K – 1003
2025
Q1 		$187K Buy
+17,834
New +$255K 0.02% 871

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's DYN Position: Q2 2025 in Review

Nebula Research & Development sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 17,834 shares — an estimated $187K sold.

Nebula Research & Development first reported a position in DYN in Q1 2025 and held it in 1 quarter. The position peaked at $187K in Q1 2025. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Nebula Research & Development reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 17,834 Dyne Therapeutics shares in Q2 2025, an estimated $187K.
  • Nebula Research & Development first reported a position in Dyne Therapeutics in Q1 2025 and held it in 1 quarter.
  • Nebula Research & Development's Dyne Therapeutics position peaked at $187K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.